Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice

Fenofibrate is widely used in clinical therapy to effectively ameliorate the development of non-alcoholic fatty liver disease (NAFLD); however, its specific molecular mechanism of action remains largely unknown. MicroRNAs (miRNAs) are key mediators in regulating endoplasmic reticulum (ER) stress dur...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Dan, Niu, Shanzhuang, Ma, Yicheng, Chen, Hang, Wen, Yu, Li, Mingke, Zhou, Bo, Deng, Yi, Shi, Chunjing, Pu, Guangyu, Yang, Meng, Wang, Xianmei, Zou, Chenggang, Chen, Yuanli, Ma, Lanqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807641/
https://www.ncbi.nlm.nih.gov/pubmed/35126113
http://dx.doi.org/10.3389/fphar.2021.770652

Ejemplares similares

Ejemplares similares